In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Torrent Pharmaceuticals Ltd.

www.torrentpharma.com

Latest From Torrent Pharmaceuticals Ltd.

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Asia Pacific Biosimilars

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Asia Pacific Biosimilars

Humira Biosimilars Face Complex Asia Outlook As Launches Edge Closer

The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.

Biosimilars Market Access

Swift And Nimble – Alembic Laps Up US Valsartan Windfall In Q2

Alembic moved fast and seized supply opportunities for valsartan, the hypertension drug that has seen shortages in the US, though management maintains that fundamental changes to the US market are there to stay given the backdrop of buying power of distributors.
Commercial Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Torrent Pharmaceuticals Ltd.
  • Senior Management
  • Sudhir Mehta, Chmn.
  • Contact Info
  • Torrent Pharmaceuticals Ltd.
    Phone: (91) 79 2658 5090
    Torrent House, Off. Ashram Rd.
    Ahmedabad, 380 009
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register